#USA #New York #Class Action #Pomerantz LLP #Medpace Holdings

Overview

The Pomerantz Law Firm has recently drawn attention to a significant development concerning Medpace Holdings, Inc. This class action lawsuit has been initiated for investors who have sustained losses on their investments in Medpace, a company listed on NASDAQ under the symbol MEDP. Investors are urged to engage with the law firm to explore their options and participate in the legal proceedings that could impact their financial future.

Details of the Class Action

Investors who acquired Medpace securities during the specified Class Period may have the opportunity to be appointed as Lead Plaintiff in the lawsuit. The deadline for expressing interest is set for June 8, 2026. Interested investors can reach out to Danielle Peyton via email or phone, providing their contact details and the number of shares they purchased.

The core of this lawsuit revolves around allegations of securities fraud and inappropriate business practices purportedly committed by Medpace and certain of its management team. Investors are encouraged to scrutinize the circumstances surrounding Medpace's recent actions that led to these claims.

Impact of Recent Earnings Report

A pivotal moment for Medpace occurred on February 9, 2026, when the company disclosed its fourth-quarter earnings for 2025. The report revealed a book-to-bill ratio of 1.04, which significantly fell short of Medpace's guidance. This disappointing news triggered a steep decline in the company's stock price, plummeting by $84.30 per share or 15.9% to close at $446.05 on February 10, 2026. Such a substantial drop highlights the volatility in the market and the potential repercussions for investors holding Medpace securities.

About Pomerantz Law Firm

Pomerantz LLP is recognized as a leading firm in the areas of corporate and securities litigation, with its headquarters in New York and offices across several major cities including Chicago, Los Angeles, London, Paris, and Tel Aviv. Established by the notable Abraham L. Pomerantz, the firm has dedicated over 85 years to advocating for victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. They have a history of securing substantial damages for class members, reaffirming their commitment to investor rights.

Conclusion

This class action against Medpace Holdings poses an essential opportunity for affected investors to join forces and seek justice for their financial losses. With upcoming deadlines, it’s crucial for those impacted to act promptly and to consult with Pomerantz LLP regarding their potential claims. For more details and to access necessary documents, investors can visit the Pomerantz Law Firm's official website.

• ---

Contact Information:
Danielle Peyton
Email: [email protected]
Phone: 646-581-9980 ext. 7980